Amylyx Pharmaceuticals Charts Path to 2026 Trial Data

Amylyx Pharmaceuticals, Inc. ((AMLX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Amylyx Pharmaceuticals’ latest earnings call carried a cautiously optimistic tone as management highlighted strong execution on its late‑stage avexitide program while acknowledging rising expenses and the pivotal risk around the upcoming LUCIDITY data. Investors heard a story of disciplined progress toward a 2026 Phase III readout and a potential 2027 launch, backed by a solid but shrinking cash cushion.

Pivotal LUCIDITY Trial Reaches Full Enrollment

Amylyx reported that it randomized and dosed the last participant in the Phase III LUCIDITY trial in late March, marking full enrollment for the 16‑week study of avexitide in post‑bariatric hypoglycemia. The trial is powered at 90% and designed to mirror earlier studies that showed roughly 55% and 64% reductions in severe hypoglycemic events, setting up a crucial top‑line readout in Q3 2026.

Regulatory Work Accelerates Toward an NDA

Management stressed that avexitide holds FDA Breakthrough Therapy designation, a status that can streamline regulatory interactions. The company is already drafting sections of a future new drug application so that, if LUCIDITY succeeds, it can compress the usual post‑Phase III timeline and move more quickly toward a filing.

Building the Commercial Engine for a 2027 Launch

Amylyx is ramping commercial readiness, hiring across marketing, market access and operations in anticipation of a potential U.S. launch in 2027. An upcoming disease‑state education campaign will target clinicians treating post‑bariatric patients, and management cites claims data suggesting about 160,000 U.S. patients with PBH after common bariatric surgeries.

Expanded Access Program Targets High‑Need Patients

To address immediate unmet need, the company has launched a U.S. expanded access program that can provide avexitide to up to 250 adults with post‑bariatric hypoglycemia. Initial eligibility focuses on patients who have completed LUCIDITY or prior avexitide trials, potentially deepening real‑world experience ahead of any approval.

Pipeline Beyond Avexitide Gains Momentum

Beyond avexitide, Amylyx is advancing several programs, including AMX0318, where IND‑enabling studies are underway and a 2027 IND filing is targeted, triggering a $4.0 million milestone recognition. The company also plans to share week‑96 data from the Phase II HELIOS study of AMX0035 in Wolfram syndrome and has fully enrolled Cohort 2 in the Phase I LUMINA trial of AMX0114 for ALS.

Cash Runway Into 2028 Supports Key Milestones

At quarter end, Amylyx held $279.8 million in cash and marketable securities, which management says should fund operations into 2028. This runway is expected to cover major milestones, including the LUCIDITY top‑line readout in Q3 2026 and a potential FDA approval and commercial rollout of avexitide in 2027.

Cash Balance Declines, Raising Execution Stakes

Despite the robust cash position, balances fell from $317.0 million a year earlier to $279.8 million, an 11.7% decline. This drop underscores how much the company now depends on hitting clinical and regulatory milestones on schedule to avoid pressures that could arise from an extended burn.

R&D Spend Climbs With Avexitide Investment

Total operating expenses rose 16% year over year to $43.8 million, reflecting heavier investment in development. Research and development costs increased to $27.6 million from $22.1 million, a 24.9% jump largely attributed to expanding clinical work around avexitide and the broader pipeline.

SG&A and One‑Off Outlays Edge Higher

Selling, general and administrative expenses edged up to $16.2 million from $15.7 million, a 3.2% increase tied mainly to consulting and professional support for launch preparations. Cash usage was further elevated by a $4.0 million milestone payment to Gubra and the payment of the annual corporate bonus, highlighting some non‑recurring but meaningful outflows.

Key Risks Around LUCIDITY and Early Biomarkers

Management acknowledged that the main value catalyst remains the LUCIDITY top‑line result in Q3 2026, and until those data are in hand clinical and regulatory risk remains elevated. Early biomarker readouts from the lowest‑dose Cohort 1 of AMX0114 may be modest, and higher dosing may be needed to show clear target engagement, limiting near‑term confidence in efficacy signals from that program.

Guidance Points to 2026 Data and Potential 2027 Launch

The company reiterated that LUCIDITY is fully enrolled, testing 90 mg once daily avexitide over 16 weeks with an FDA‑agreed primary endpoint focused on severe hypoglycemic events and a top‑line readout planned for Q3 2026. Management continues to target a 2027 FDA decision and commercial launch, supported by a cash runway into 2028, ongoing expanded access for up to 250 patients and a pipeline paced toward key 2027 inflection points.

Amylyx’s call painted a picture of a company leaning into its late‑stage opportunity while managing the financial strain that comes with it. With LUCIDITY fully enrolled, commercial infrastructure forming and a pipeline advancing in parallel, the investment case now pivots on whether avexitide can deliver in 2026 and translate breakthrough‑level data into a durable commercial franchise.